Effectiveness and Durability of the BNT162b2 Vaccine against Omicron Sublineages in South Africa

N Engl J Med. 2022 Oct 6;387(14):1332-1333. doi: 10.1056/NEJMc2210093. Epub 2022 Sep 14.

Authors

Shirley Collie¹, Jiren Nayager¹, Lesley Bamford², Linda-Gail Bekker³, Matt Zylstra¹, Glenda Gray⁴

Affiliations

¹ Discovery Health, Sandton, South Africa.
² National Department of Health, Pretoria, South Africa.
³ Desmond Tutu HIV Foundation, Cape Town, South Africa.
⁴ South African Medical Research Council, Cape Town, South Africa glenda.gray@mrc.ac.za.

No abstract available

Publication types

Letter

MeSH terms

BNT162 Vaccine* / immunology
BNT162 Vaccine* / therapeutic use
COVID-19* / epidemiology
COVID-19* / etiology
COVID-19* / prevention & control
Humans
SARS-CoV-2* / genetics
SARS-CoV-2* / immunology
South Africa / epidemiology
Vaccination
Vaccine Efficacy

Substances

BNT162 Vaccine

Supplementary concepts

SARS-CoV-2 variants